Steven Cohen’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-398,463
Closed -$4.98M – 4367
2026
Q2
$6.74M Buy
398,463
+128,452
+48% +$1.8M 0.01% 1558
2026
Q1
$3.46M Buy
+270,011
New +$3.44M ﹤0.01% 1946
2025
Q4
– Sell
-174,261
Closed -$2.4M – 4086
2025
Q3
$3.01M Buy
+174,261
New +$2.15M 0.01% 1275
2021
Q2
– Sell
-180,400
Closed -$14.5M – 1106
2021
Q1
$14.5M Buy
180,400
+34,900
+24% +$2.34M 0.07% 339
2020
Q4
$7.92M Sell
145,500
-507,619
-78% -$18.4M 0.04% 493
2020
Q3
$13M Sell
653,119
-217,788
-25% -$4.54M 0.07% 353
2020
Q2
$18.3M Buy
+870,907
New +$14.8M 0.12% 225

Other funds holding NTLA

Steven Cohen's NTLA Position: Q3 2026 in Review

Steven Cohen sold out of Intellia Therapeutics (NTLA) in Q3 2026, closing a stake of 398,463 shares — an estimated $4.98M sold.

Steven Cohen first reported a position in NTLA in Q2 2020 and held it in 7 quarters. The position peaked at $18.3M in Q2 2020. 312 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • Steven Cohen reported no remaining Intellia Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Steven Cohen sold 398,463 Intellia Therapeutics shares in Q3 2026, an estimated $4.98M.
  • Steven Cohen first reported a position in Intellia Therapeutics in Q2 2020 and held it in 7 quarters.
  • Steven Cohen's Intellia Therapeutics position peaked at $18.3M in Q2 2020.
  • 312 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.